Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Breo Breathing A Little Easier In Asthma, But More Studies Ahead

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA advisory committee votes recommends Breo Ellipta for asthma in adults with post-approval safety study, but panel wants additional premarket efficacy and safety data for adolescents.

Advertisement

Related Content

Asthma Warnings Not Working Well, FDA Fears As GSK Seeks Expanded LABA Approval
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078276

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel